scholarly journals Cross-cultural Validation of the Brazilian Portuguese Version of the McGill Quality of Life Questionnaire

2014 ◽  
Vol 1 (3) ◽  
Author(s):  
Jose Eluf-Neto
2001 ◽  
Vol 15 (5) ◽  
pp. 387-397 ◽  
Author(s):  
Raymond S K Lo ◽  
Jean Woo ◽  
Karen C H Zhoc ◽  
Charlotte Y P Li ◽  
Winnie Yeo ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
E. Dias de Castro ◽  
J. Barbosa ◽  
A. M. Mesquita ◽  
A. Caires ◽  
L. Ribeiro ◽  
...  

Abstract Background Hypersensitivity reactions to drugs are unpredictable and can be very complex and severe, even life threatening. Assess its impact on patient’s health related quality of life (HRQoL) is crucial. The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is the only validated disease-specific HRQoL questionnaire. We aimed to translate and cross-cultural validate the DrHy-Q to the Portuguese population. It was also our purpose to determine the impact of drug hypersensitivity on patients’ HRQoL. Methods The translation and cross-cultural adaptation of the DrHy-Q to Portuguese was performed according to standards. Reliability of the DrHy-Q Portuguese version was assessed in terms of internal consistency and test–retest reliability. Structural validity, divergent validity (with a generic health related QoLQ-PGWBI) and discriminant validity were also evaluated. Forty patients accepted to participate in the validation phase. The Portuguese version of the DrHy-Q was applied to 260 consecutively adult patients, studied in our Department for suspected drug hypersensitivity. Results The Portuguese DrHy-Q showed adequate internal consistency (Cronbach’s ɑ = 0.938), good test–retest reliability [ICC = 0.713 (95% CI 0.488–0.850] and one-dimensional structure. No significant correlation was found between the DrHy-Q and the PGWBI total scores (r = − 0.010, p = 0.957). Two hundred of patients completed the study: 78.5% female; mean age = 44 ± 15 years. Mean DrHy-Q score was 36.8 ± 12.6. Two clinical factors significantly predict DrHy-Q total score: clinical manifestations and number of suspected drugs. Patients with anaphylaxis (β = 11.005; 95% CI 5.523; 16.487), urticaria/angioedema (β = 7.770; 95% CI 2.600; 12.940) and other manifestations (β = 7.948; 95% CI 1.933; 13.962) are more likely to have higher DrHy-Q total score than patients with maculopapular exanthema. Patients with ≥ 2 suspected drugs are also more likely to have worse QoL (β = 7.927; 95% CI 3.687; 12.166). Conclusion The Portuguese version of DrHy-Q revealed adequate validity and reliability, indicating that it is appropriate to assess the impact of drug hypersensitivity on patients’ HRQoL, providing data for a better comprehension and management of our patients. Moreover, our results highlight that the severity of the drug hypersensitivity reaction and the number of suspected drugs have impact on patient’s DrHy-QoL.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Rosalie Power ◽  
Rahena Akhter ◽  
Mohammad Muhit ◽  
Sabrina Wadud ◽  
Eamin Heanoy ◽  
...  

2017 ◽  
Vol 30 (1) ◽  
pp. 47 ◽  
Author(s):  
Miguel Relvas-Silva ◽  
Rui Almeida Silva ◽  
Mário Dinis-Ribeiro

Introduction: Health-related quality of life assessment is increasingly important as it can help both clinical research and care for patients, particularly among oncological patients. Quality of Life Questionnaire – OES18 (esophageal module) and Quality of Life Questionnaire – OG25 (esophagogastric module) are the European Organization for Research and Treatment of Cancer modules for the evaluation of quality of life in patients with esophageal and esophagogastric cancers, respectively. The aim of our study was to translate, to culturally adapt and to perform a pilot testing to create the Portuguese version of both questionnaires.Material and Methods: The European Organization for Research and Treatment of Cancer guidelines were followed for translation, cultural adaptation and pilot testing of Quality of Life Questionnaire – OES18 (esophageal module) and Quality of Life Questionnaire – OG25 (esophagogastric module). The Quality of Life Questionnaire – OG25 (esophagogastric module) went through a process of forward (English → Portuguese) and backward (Portuguese → English) translation, by independent native speaker translators. After review, a preliminary version was created to be pilot tested among Portuguese patients. As a Brazilian version was already available for Quality of Life Questionnaire – OES18 (esophageal module), the questionnaire was simply culturally adapted and pilot tested. Both cancer and non-cancer patients were included.Results: Overall, 30 patients completed the Portuguese version of each questionnaire. Afterwards, a structured interview was conducted to find and report any problematic items. Troublesome items and wording were changed according to the pilot testing results. The final versions were sent to the European Organisation for Research and Treatment of Cancer Quality of Life Group and approved.Conclusion: The Portuguese versions of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – OES18 (esophageal module) and OG25 (esophagogastric module) questionnaires are useful, reliable and valid tools for measuring health-related quality of life in patients with esophageal and esophagogastric cancers, respectively. They can now be used in clinical setting and for scientific purposes.


Sign in / Sign up

Export Citation Format

Share Document